Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 7700
- Registration Number
- NCT03431142
- Locations
- 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03392051
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT03385538
- Locations
- 🇩🇰
Zealand University Hospital, dept of neurology, Roskilde, Denmark
Efficacy and Safety of Low-dose Ticagrelor
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2019-09-30
- Target Recruit Count
- 3043
- Registration Number
- NCT03381742
- Locations
- 🇨🇳
Thromboela-Stogram, Beijing, China
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT03378934
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 514
- Registration Number
- NCT03357874
- Locations
- 🇫🇷
APHM, Marseille, France
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Laboratoires Teriak
- Target Recruit Count
- 167
- Registration Number
- NCT03329261
- Locations
- 🇹🇳
HMPIT, Ben Arous, Tunisia
Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2017-09-21
- Target Recruit Count
- 877
- Registration Number
- NCT03289520
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Boston University Medical Center, Boston, Massachusetts, United States
Anti-platelet + Pembro for H&N Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT03245489
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Thorax Centrum Twente
- Target Recruit Count
- 2062
- Registration Number
- NCT03197298
- Locations
- 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.